[24 May 2012]
Products Affected - Description
Primatene Mist Inhaler (CFC), Armstrong Pharmaceuticals
0.22 mg/actuation, Over-the-Counter
Reason for the Shortage
- To decrease depletion of the ozone layer, the Food and Drug Administration (FDA) announced that epinephrine metered dose inhalers (MDIs) containing chlorofluorocarbon (CFC) propellant must be withdrawn from the market by December 31, 2011.
- Other prescription metered dose inhalers such as albuterol were previously transitioned from a CFC propellant to a hydrofluoroalkane (HFA) propellant in 2008.
- Armstrong Pharmaceuticals is the only manufacturer of over-the-counter epinephrine inhalers. Patients will now need a prescription for any type of metered-dose inhaler. Additional information for patients is available online.
- Armstrong discontinued Primatene Mist with CFC propellant at the end of 2011. The company is hoping to release a more environmentally friendly Primatene Mist in the near future.
Estimated Resupply Dates
- Armstrong discontinued Primatene Mist with CFC propellant in December 31, 2011.
- There are no other over-the-counter epinephrine metered dose inhalers available.
May 24, 2012; February 7, 2012; October 12, 2011, University of Utah, Drug Information Service. Copyright 2012, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins